# Jakub Radocha

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4973783/publications.pdf

Version: 2024-02-01

| 65 | 421 | 840119 11 | 887659 17 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 70 | 70 | 70 | 764 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia, 2022, 36, 288-291. | 3.3 | 23 |
| 2 | Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer, 2021, 21, 73. | 1.1 | 20 |
| 3 | Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. Cancers, 2021, 13, 1571. | 1.7 | 21 |
| 4 | Bortezomibâ€based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. European Journal of Haematology, 2021, 107, 466-474. | 1.1 | 1 |
| 5 | Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective realâ€world confirmation. International Journal of Laboratory Hematology, 2021, 43, e244-e247. | 0.7 | 1 |
| 6 | Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome. Leukemia Research Reports, 2021, 16, 100274. | 0.2 | 1 |
| 7 | Identification of patients at high risk of secondary extramedullary multiple myeloma development. British Journal of Haematology, 2021, , . | 1.2 | 8 |
| 8 | Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice. Blood, 2021, 138, 2716-2716. | 0.6 | 1 |
| 9 | Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic. Blood, 2021, 138, 4894-4894. | 0.6 | 0 |
| 10 | Oral Mucositis Association with Periodontal Status: A Retrospective Analysis of 496 Patients Undergoing Hematopoietic Stem Cell Transplantation. Journal of Clinical Medicine, 2021, 10, 5790. | 1.0 | 4 |
| 11 | BAL fluid analysis in the identification of infectious agents in patients with hematological malignancies and pulmonary infiltrates. Folia Microbiologica, 2020, 65, 109-120. | 1.1 | 8 |
| 12 | Identification of patients with smouldering multiple myeloma at ultraâ€high risk of progression using serum parameters: the Czech Myeloma Group model. British Journal of Haematology, 2020, 190, 189-197. | 1.2 | 13 |
| 13 | A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. American Journal of Hematology, 2020, 95, 503-509. | 2.0 | 11 |
| 14 | Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893. | 0.6 | 3 |
| 15 | EFFECTS OF FLUOROQUINOLONE RESTRICTION INÂTHEÂHOSPITAL ON THE DEVELOPMENT OFÂSENSITIVITY OF SELECTED BACTERIAL PATHOGENS. Military Medical Science Letters (Vojenske Zdravotnicke Listy), 2020, 89, 178-189. | 0.2 | 0 |
| 16 | Iron Deficiency as Cause of Dysphagia and Burning Mouth (Plummer-Vinson or Kelly-Patterson) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14 | 0.2 | 0 |
| 17 | Oral Manifestations of Nutritional Deficiencies: Single Centre Analysis. Acta Medica (Hradec Kralove), 2020, 63, 95-100. | 0.2 | 1 |
| 18 | Improved laboratory diagnostics of Streptococcus pneumoniae in respiratory tract samples through qPCR. New Microbiologica, 2020, 43, 70-77. | 0.1 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Clinical and genotypic CMV drug resistance in HSCT recipients: a single center epidemiological and clinical data. Bone Marrow Transplantation, 2019, 54, 146-149. | 1.3 | 4 |
| 20 | Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. British Journal of Haematology, 2019, 187, 447-458. | 1.2 | 7 |
| 21 | Hematogenous extramedullary relapse in multiple myeloma â€•a multicenter retrospective study in 127 patients. American Journal of Hematology, 2019, 94, 1132-1140. | 2.0 | 24 |
| 22 | Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma â€“ analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Neoplasma, 2019, 66, 499-505. | 0.7 | 4 |
| 23 | Urine immunofixation is not necessary for CR definition in myeloma patients with complete M protein molecule. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e180-e181. | 0.2 | 0 |
| 24 | Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e271-e272. | 0.2 | 1 |
| 25 | Registry of Monoclonal Gammopathies (RMG) - the monitored real-world database of the Czech Myeloma Group. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e324-e325. | 0.2 | 0 |
| 26 | Simplified novel prognostic score for real-life older adults with multiple myelomaâ€”registry-based analysis. Annals of Hematology, 2019, 98, 951-962. | 0.8 | 2 |
| 27 | Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG). Blood, 2019, 134, 3139-3139. | 0.6 | 2 |
| 28 | Ciprofloxacin prophylaxis during autologous stem cell transplantation for multiple myeloma in patients with a high rate of fluoroquinolone-resistant gram-negative bacteria colonization. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2019, 163, 161-165. | 0.2 | 3 |
| 29 | Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 1372-1378. | 2.0 | 20 |
| 30 | Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. British Journal of Haematology, 2018, 180, 831-839. | 1.2 | 41 |
| 31 | Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience. Folia Microbiologica, 2018, 63, 141-146. | 1.1 | 11 |
| 32 | Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Cancer Medicine, 2018, 7, 4132-4145. | 1.3 | 6 |
| 33 | Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib,) Tj ETQq1 1 0.784314 rgBT /Overlock 1 0 1 1959-1959. | 0.6 | 4 |
| 34 | The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. Blood, 2018, 132, 4452-4452. | 0.6 | 3 |
| 35 | Detection of cytomegalovirus DNA in fecal samples in the diagnosis of enterocolitis after allogeneic stem cell transplantation. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2018, 162, 227-231. | 0.2 | 2 |
| 36 | Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. Blood, 2018, 132, 2004-2004. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Treatment Outcomes of Real Life Elderly Multiple Myeloma Patients:Ã, Analysis from Registry of Monoclonal Gammopathies (RMG). Blood, 2018, 132, 2019-2019. | 0.6 | 0 |
| 38 | Risk Factors Associated with Development of Extramedullary Disease in Multiple Myeloma. Blood, 2018, 132, 5596-5596. | 0.6 | 0 |
| 39 | A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. European Journal of Haematology, 2017, 99, 80-90. | 1.1 | 7 |
| 40 | Human polyomavirus 9 in immunocompromised patients in the University Hospital in Hradec Kralove, Czech Republic. Journal of Medical Virology, 2017, 89, 2230-2234. | 2.5 | 3 |
| 41 | Treatment of Multifocal Multisystem BRAF Positive Langerhans Cell Histiocytosis with Cladribine, Surgery and Allogenic Stem Cell Transplantation. Acta Medica (Hradec Kralove), 2017, 60, 152-156. | 0.2 | 3 |
| 42 | Plasmacytic Post-transplant Lymphoproliferative Disorder â€“ Case Report. European Oncology and Haematology, 2017, 13, 80. | 0.0 | 3 |
| 43 | Multicentered patientâ€based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. European Journal of Haematology, 2016, 96, 119-127. | 1.1 | 8 |
| 44 | Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population. Blood, 2016, 128, 3333-3333. | 0.6 | 3 |
| 45 | Simple Prognostic Score for Evaluation of Elderly Multiple Myeloma Patients. Blood, 2016, 128, 5679-5679. | 0.6 | 1 |
| 46 | Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2016, 128, 993-993. | 0.6 | 9 |
| 47 | Oral manifestation of sarcoidosis: A case report and review of the literature. Journal of Indian Society of Periodontology, 2016, 20, 627. | 0.3 | 8 |
| 48 | Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy. PLoS ONE, 2015, 10, e0123866. | 1.1 | 32 |
| 49 | Autologous stem cell collection after biosimilar G-CSF (ZarzioÂ®) compared to original G-CSF (NeupogenÂ®) in multiple myeloma patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e167. | 0.2 | 0 |
| 50 | Registry of Monoclonal Gammopathies (RMG) in the Czech Republic. Blood, 2015, 126, 4514-4514. | 0.6 | 11 |
| 51 | Stem Cell Mobilization after Various Induction Regimens in Patients with Multiple Myeloma. Blood, 2015, 126, 5433-5433. | 0.6 | 0 |
| 52 | NK/T-cell lymphoma nasal type with an unusual clinical course. Indian Journal of Dermatology, Venereology and Leprology, 2014, 80, 564. | 0.2 | 3 |
| 53 | Extracorporeal elimination in familial hypercholesterolemia â€“ comparison of two methods. Transfusion and Apheresis Science, 2014, 50, S18. | 0.5 | 0 |
| 54 | Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients]. Blood, 2014, 124, 2071-2071. | 0.6 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic. Blood, 2014, 124, 3376-3376. | 0.6 | 1 |
| 56 | Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group. Blood, 2014, 124, 2117-2117. | 0.6 | 0 |
| 57 | Sequential Allogeneic Stem Cell Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2013, 19, S312. | 2.0 | 0 |
| 58 | 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group. Leukemia Research, 2013, 37, 1063-1069. | 0.4 | 3 |
| 59 | FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS. Acta Medica (Hradec Kralove), 2013, 56, 9-13. | 0.2 | 2 |
| 60 | High-Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma Group. Blood, 2012, 120, 4528-4528. | 0.6 | 0 |
| 61 | Association Study of Selected Genetic Polymorphisms and Occurrence of Venous Thromboembolism in Patients With Multiple Myeloma Who Were Treated With Thalidomide. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 414-420. | 0.2 | 10 |
| 62 | Pneumocystis Pneumonia During Medicamentous Treatment of Cushingâ€™s Syndrome â€“ A Description of Two Cases. Acta Medica (Hradec Kralove), 2011, 54, 127-130. | 0.2 | 6 |
| 63 | High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. Bone Marrow Transplantation, 2008, 41, 51-54. | 1.3 | 19 |
| 64 | Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. European Journal of Haematology, 2007, 79, 305-309. | 1.1 | 9 |
| 65 | The role of intracellular zinc in modulation of life and death of Hep-2 cells. BioMetals, 2003, 16, 295-309. | 1.8 | 19 |